

# KCMS ADC MONITORING GUIDE

## Managing Ocular and Nerve Effects in Antibody-Drug Conjugate (ADC) Therapy

**Purpose:** To support early recognition, prevention, and management of ocular and peripheral nerve toxicities associated with ADCs such as tisotumab vedotin (Tivdak) used in recurrent or metastatic cervical cancer.

### Baseline Evaluation

- ✓ Conduct a comprehensive ophthalmologic exam (visual acuity, slit-lamp, ocular surface evaluation).
- ✓ Assess for pre-existing neuropathy or ocular conditions.
- ✓ Educate patients on eye-drop prophylaxis and cooling eye mask use during infusion.
- ✓ Document baseline findings in the EHR.

### During Each Treatment Cycle

- ✓ Review symptoms at every visit: blurred vision, eye pain, tearing, dryness, redness.
- ✓ Ask about numbness, tingling, or burning sensations in hands or feet.
- ✓ Reassess ocular surface integrity if symptoms develop.
- ✓ Reinforce patient education on drop schedules and hand hygiene.
- ✓ Encourage immediate reporting of new or worsening eye or nerve symptoms.

### When to Hold or Modify Therapy

- Ocular Toxicity:
  - Hold therapy for Grade  $\geq 2$  ocular events (per CTCAE v5.0).
  - Resume at reduced dose once resolved to Grade  $\leq 1$ .
  - Consult ophthalmology prior to re-initiation.
- Peripheral Neuropathy:
  - Hold therapy for Grade 2 neuropathy; resume at reduced dose upon improvement.
  - Discontinue permanently for Grade  $\geq 3$  neuropathy.

### Supportive Measures

- Eye Protection: Apply vasoconstrictor eye drops and lubricants before, during, and after infusion.
- Cold Compress: Use during infusion to minimize drug exposure to ocular tissues.
- Prevent Dryness: Artificial tears QID throughout treatment.
- Safety Monitoring: Coordinate with ophthalmology and neurology teams as needed.

### ✓ Fast Action

- Use this guide during infusion chairside or tumor board review.
- Integrate into nursing protocols for patients receiving ADC therapy.

Sources: NCCN Guidelines: Cervical Cancer, 2025;  
FDA Prescribing Information, Tisotumab Vedotin (Tivdak).